MODULE 4: Diabetic Retinopathy – Current Diagnosis and Management with an “Eye” to the Future

David DiLoreto, MD, PhD

Program Description
This update will summarize the historical treatments of diabetic retinopathy, what the current treatment for diabetic retinopathy currently are, and what the future may hold.

Learning Objectives
At the conclusion of this activity, participants should be able to:

• Describe the laser treatment of diabetic retinopathy.
• Explain the intravitreal pharmacologic treatment of diabetic retinopathy.

Bibliographic Sources to Allow for Further Study


Accreditation
The University of Rochester School of Medicine and Dentistry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Certification
The University of Rochester School of Medicine and Dentistry designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

No commercial funds have been received to support this educational activity.

Planning Committee / Speaker Disclosures
The following speakers have disclosed financial interests/arrangements or affiliations with organization(s) that could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation(s). Only the current arrangements/interests are included.

*Planning Committee Members

David DiLoreto, MD, PhD  Speaker declared that no financial interest or relationship exists
Tamara Eis, MS, RN-BC*  Planner declared that no financial interest or relationship exists
Stephen Hammes, MD, PhD*  Planner declared that no financial interest or relationship exists
Heidi Kipp, NP*  Planner declared that no financial interest or relationship exists
Steven Wittlin, MD*  Planner declared Consultant for Sensionics and Speakers’ Bureau for Medtronic Diabetes

The Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support require that presentations are free of commercial bias and that any information regarding commercial products/services be based on scientific methods generally accepted by the medical community. When discussing therapeutic options, speakers are requested to use only generic names. If they use a trade name, then those of several companies should be used. If a presentation includes discussion of any unlabeled or investigational use of a commercial product, speakers are required to disclose this to the participants.